PROBISEARCH, leading company in probiotic research, has recently completed patient recruitment and participation in the PREBIOMA study and is now conducting statistical analyses of results.
The microbiota of vaginally born, full-term healthy babies, who need no medication and are exclusively breastfed is considered to be the ideal microbiota at that age.
This optimal bacterial colonization however may be altered by the type of delivery, diet, use of antibiotics and/or premature birth. Premature babies show an alteration in the development of intestinal microbiota, which has been described as aberrant. Generally, the alterations involve increased prevalence of potentially pathogenic bacteria, high variability among individuals and lower microbial diversity compared with full-term babies
The primary objective of the PREBIOMA study is to investigate the effect of probiotic strains Lactobacillus sp. and Bifidobacterium sp. on the colonization of the intestinal tract in premature babies.
Additionally the study is also intended to investigate the effect of the above probiotic strains on the composition of total microbiota and the immune cells in the gastrointestinal tract; to assess the incidence of Necrotizing Enterocolitis (NEC) and sepsis, and to quantify the number of hospital days in the Neonatal Unit and effect on weight gain, length and head circumference of newborns.
The study is conducted in collaboration with Dr. Miguel Sáenz de Pipaón from La Paz University Hospital (Madrid).
PROBISEARCH has a Clinical Trial Department with expertise in the design, implementation, development and follow-up of clinical trials with probiotics. Trials are conducted in accordance with local and international Good Clinical Practices.
PROBISEARCH is located in Madrid Technology Park. Founded in 2011 by a group of scientists from the Complutense University of Madrid, PROBISEARCH’s mission is to offer new probiotic products to prevent and treat a range of human and animal diseases where the microbiota plays a role.
PROBISEARCH was acquired in 2016 by biotechnology group Zendal with the aim of continuing with this mission, and integrating this knowledge and expertise within a more wide-ranging offering in the field of Probiotics for human and animal health.